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Abstract
Background: The prevalence, treatment and outcomes of balloon undilatable chronic total occlu-
sions (CTOs) have received limited study.
Methods: We examined the prevalence, clinical and angiographic characteristics, and procedural
outcomes of percutaneous coronary interventions (PCIs) for balloon undilatable CTOs in a contem-
porary multicenter US registry.
Results: Between 2012 and 2017 data on balloon undilatable lesions were available for 425 con-
secutive CTO PCIs in 415 patients in whom guidewire crossing was successful: 52 of 425 CTOs
were balloon undilatable (12%). Mean patient age was 65610 years and most patients were men
(84%). Patients with balloon undilatable CTOs were more likely to be diabetic (67 vs. 41%,
P<0.001) and have heart failure (44 vs. 28%, P50.027). Balloon undilatable CTOs were longer
(40 mm [interquartile range, IQR 20-50] vs. 30 [IQR 15-40], P50.016), more likely to have moder-
ate/severe calcification (87 vs. 54%, P<0.001), and had higher J-CTO score (3.261.1 vs. 2.56
1.3, P<0.001) and PROGRESS-CTO complications score (3.961.7 vs. 3.162.0, P<0.005). They
were associated with lower technical and procedural success (92 vs. 98%, P50.024; and 88 vs.
96%, P50.034, respectively) and higher risk for in-hospital major adverse events (8 vs. 2%,
P50.008) due to higher perforation rates. The most frequent treatments for balloon undilatable
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CTOs were high pressure balloon inflations (64%), rotational atherectomy (31%), laser (21%), and
cutting balloons (15%).
Conclusions: Balloon undilatable CTOs are common and are associated with lower success and
higher complication rates.
K E YWORD S
chronic total occlusion, complex coronary intervention, percutaneous coronary intervention
1 | INTRODUCTION
Chronic total occlusion (CTO) percutaneous coronary intervention
(PCI) has been rapidly evolving with high success rates currently
being achieved at experienced centers [1–6]. Although failure to
cross the occlusion with a guidewire is the most common mecha-
nism of CTO PCI failure, additional technical challenges exist, such
as inability to advance a balloon after successful guidewire cross-
ing (balloon uncrossable lesions) [7–9], and inability to fully dilate
the lesion despite multiple balloon inflations (balloon undilatable
lesions) (Figure 1). Adequate preparation in such lesions is critical
to avoid suboptimal stent expansion that can result in higher rates
of stent thrombosis and in-stent restenosis [10,11]. In view of con-
tinuing advancements in CTO crossing devices and techniques, the
prevalence of balloon uncrossable and undilatable lesions is likely
to increase. We, therefore, examined a large multicenter US CTO
PCI registry to determine the frequency, treatment, and outcomes
of balloon undilatable lesions.
2 | METHODS
We examined the frequency and the baseline clinical, angiographic, and
procedural characteristics and outcomes of balloon undilatable lesions
in the PROGRESS CTO (Prospective Global Registry for the Study of
CTO Intervention, NCT02061436). Data collection on balloon undilat-
able lesions started in 2015. The study was approved by the institu-
tional review board of each center.
2.1 | Definitions
Coronary CTOs were defined as coronary lesions with thromboly-
sis in myocardial infarction (TIMI) grade 0 flow of at least 3-month
duration. Estimation of the duration of occlusion was based on the
first onset of angina, prior history of myocardial infarction (MI) in
the target vessel territory, or comparison with a prior angiogram.
Balloon undilatable CTOs were defined as lesions that could not
be expanded despite multiple balloon inflations with a 1:1 sized
balloon at a maximum inflation pressure up to 20 atm after suc-
cessful guidewire crossing, and balloon advancement within the
target lesion. Balloon uncrossable lesions were defined as lesions
that could not be crossed by balloon after successful guidewire
crossing into the true lumen distal to the occlusion. Balloon infla-
tions >20 atm were defined as high-pressure. Calcification assess-
ment was based on angiography as follows: mild (spots), moderate
(involving 50% of the reference lesion diameter) and severe
(involving >50% of the reference lesion diameter). Moderate prox-
imal vessel tortuosity was defined as the presence of at least two
bends >708 or one bend >908 and severe tortuosity as two bends
>908 or one bend >1208 in the CTO vessel. Blunt or no stump was
defined as lack of tapering or lack of a funnel shape at the proxi-
mal cap. Interventional collaterals were defined as collaterals con-
sidered amenable to crossing by a guidewire and a microcatheter
by the operator.
Technical success was described as successful CTO revascu-
larization with achievement of <30% residual diameter stenosis
within the treated segment and restoration of TIMI grade 3
antegrade flow. Procedural success was defined as achievement
of technical success without any in-hospital complications. In-
hospital major adverse cardiac events (MACEs) included any of
the following adverse events prior to hospital discharge: death,
MI, recurrent symptoms requiring urgent repeat target vessel
revascularization with PCI or coronary artery bypass graft surgery
(CABG), tamponade requiring either pericardiocentesis or surgery,
and stroke. Periprocedural MI was defined using the Third
Universal Definition of MI (type 4a MI) [12]. Procedure time was
calculated from administration of local anesthetic for vascular
access to removal of the last catheter. The J-CTO score was calcu-
lated as described by Morino et al. [13], the PROGRESS-
CTO score as described by Christopoulos et al. [14], and the
PROGRESS-CTO Complications score as described by Danek et al.
[15].
2.2 | Statistical analysis
Categorical variables were described as percentages and were
compared using Pearson’s chi-square test or Fisher’s exact test.
Continuous variables were expressed as mean6 standard devia-
tion or median [interquartile range, IQR] unless otherwise speci-
fied and were compared using the t-test or Wilcoxon rank-sum
test, as appropriate. All statistical analyses were performed with
JMP 13.0 (SAS Institute, Cary, NC). A two-sided P value of 0.05
was considered statistically significant.
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3 | RESULTS
3.1 | Clinical and angiographic characteristics
Between 2015 and May 2017 data on balloon undilatable lesions was
available for 425 consecutive CTO PCIs performed in 415 patients at 9
US centers. The prevalence of balloon undilatable lesions was 12% (52
of 425). Mean patient age was 65610 years, and most patients were
men (84%). Patients with balloon undilatable lesions were more likely
to have diabetes mellitus (67 vs. 41%, P<0.001), congestive heart fail-
ure (44 vs. 28%, P50.027), and lower left ventricular ejection fraction
(45613 vs. 50613%, P50.015) (Table 1). However, the prevalence
of prior CABG (45 vs. 35%, P50.175), and dialysis (2 vs. 2%,
P51.000) were similar in the two groups.
The angiographic characteristics of the study lesions are presented
in Table 2. The most common CTO target vessel was the right coronary
artery (54%), followed by the left anterior descending artery (24%), and
left circumflex (21%). As compared with balloon dilatable lesions, bal-
loon undilatable lesions were longer (median length was 40 mm [IQR
20–50] vs. 30 mm [IQR 15–40], P50.016), and more likely to be asso-
ciated with moderate or severe calcification (87 vs. 54%, P<0.001).
They also had higher J-CTO score (3.261.1 vs. 2.561.3, P<0.001),
and PROGRESS-CTO complications score (3.961.7 vs. 3.162.0,
FIGURE 1 Challenging PCI for balloon undilatable ostial right coronary artery (RCA) CTO. A and B, Short (10 mm) ostial right coronary
artery CTO that was crossed with a Fielder FC guidewire advanced through a Caravel microcatheter (Asahi Intecc, Nagoya, Japan). C
and D, Orbital atherectomy was performed for plaque modification (18 passes), and was complicated by crown fracture and entrapment.
The fractured crown was retrieved after removal of the Viper guidewire. E, The lesion failed to dilate despited multiple balloon
inflations (2.0 3 20 and 2.5 3 20 mm balloon inflated at 20–24 Atm [red arrowhead]). F, An AngioSculpt balloon (Spectranetics,
Fremont, CA) was delivered and inflated using a GuideLiner V3 (Vascular Solutions, Minneapolis, MN) guide catheter extension. G, Rotational
atherectomy (yellow arrowhead) was attempted (eight passes, upsizing the burr diameter from 1.2 to 1.25 mm) over a RotaWire Floppy
guidewire (Boston Scientific, Natick, MA), but also failed to cross the lesion. H, Optical coherence tomography demonstrating heavy
circumferential calcification in the proximal right coronary artery. I, Final angiographic result after stenting [Color figure can be viewed at
wileyonlinelibrary.com]
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P<0.005), but similar PROGRESS CTO score (1.561.2 vs. 1.561.0,
P50.881).
3.2 | Procedural techniques
The techniques used for treating balloon undilatable lesions and the clinical
outcomes are shown in Table 3. Guidewire crossing was achieved in 44%
with antegrade wire escalation, 21% with antegrade dissection reentry,
and 35% with the retrograde approach. Bilateral injections were used in
75% and most cases were performed via femoral access (79% left femoral
access and 52% right femoral access). Intravascular ultrasound was used
more frequently in balloon undilatable lesions (65 vs. 42%, P<0.003). The
overall prevalence of balloon uncrossable lesions was 11.6% (n549), of
which 47% (n523) were also balloon undilatable as compared with 8%
among balloon crossable lesions (P<0.001). Conversely, 44% (n523) of
balloon undilatable lesions were also balloon uncrossable.
Several techniques were used for lesion preparation, such as high-
pressure balloon inflations (64%), rotational atherectomy (RA) (31%),
laser (21%), cutting balloon (15%), and AngioSculpt (Spectranetics, Fre-
mont, CA) (14%) (Table 4). Two or more techniques were used in 48%
of the undilatable lesions with higher overall technical (100 vs. 85%,
P50.112) and procedural (96 vs. 85%, P50.350) success, and lower
major complication rate (0 vs. 15%, P50.112) as compared with cases
in which only one technique was used.
3.3 | Procedural outcomes
The overall technical and procedural success rates were 98 and 95%,
respectively and were lower in balloon undilatable lesions: technical
success: 92 vs. 98%, (P50.024); procedural success: 88 vs. 96%
(P50.034) (Table 3). The median procedural (195 min [IQR 115–262]
vs. 141 min [IQR 97–205], P<0.007) and fluoroscopy time (67 min
[IQR 40–104] vs. 49 min [IQR 30–76], P<0.007) were longer in the
balloon undilatable group, but air kerma radiation dose (3 Gray [IQR 2–
4] vs. 3 Gray [2–4], P50.083) and contrast volume (284 mL [IQR 185–
315] vs. 262 mL [IQR 200–350], P50.642) were similar in the two
groups.
Procedural complications are presented in Table 5. Balloon undilat-
able lesions were associated with higher incidence of in hospital MACE
(8 vs. 2%, P50.008), due to higher incidence of coronary perforations,
including perforations causing tamponade and requiring pericardiocent-
esis (5.8 vs. 0.3%, P50.007). Perforations were most commonly
TABLE 1 Clinical characteristics of balloon undilatable and balloon dilatable CTO lesions.
Clinical characteristics
Balloon undilatable lesions Balloon dilatable lesions
P value(n5 52, 12%) (n5363, 88%)
Age (years)a 67.169.7 64.36 10.2 0.056
Male gender, n (%) 39 (75) 302 (85) 0.074
BMI (kg/m2)a 31.765.7 30.36 5.7 0.114
Smoking (current), n (%) 13 (27) 82 (24) 0.641
Diabetes, n (%) 34 (67) 146 (41) <0.001
Dyslipidemia, n (%) 51 (100) 33 (95) 0.110
Hypertension, n (%) 48 (94) 313 (88) 0.206
Family history of CAD, n (%) 17 (44) 132 (42) 0.866
Prior MI, n (%) 29 (59) 182 (52) 0.336
Prior heart failure, n (%) 22 (44) 98 (28) 0.027
Prior valve surgery or procedure, n (%) 2 (4) 14 (4) 0.969
Prior PCI, n (%) 35 (70) 221 (63) 0.336
Prior CABG, n (%) 23 (45) 125 (35) 0.175
Baseline creatinine (mg/dL)b 1 (1, 1) 1 (1, 1) 0.634
Currently on dialysis, n (%) 1 (2) 6 (2) 1.000
Prior CVD, n (%) 9 (18) 41 (2) 0.215
Prior PVD, n (%) 8 (16) 53 (15) 0.900
Chronic lung disease, n (%) 8 (16) 60 (17) 0.802
Left ventricular EF (%)a 45.2613.4 50.36 13.3 0.015
Abbreviations: BMI, body mass index; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coro-
nary artery bypass graft surgery; CVD, cerebrovascular disease; PVD, peripheral arterial disease; EF, ejection fraction.
aMean6 SD.
bMedian (IQR).
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treated with prolonged balloon inflation (67% of all cases of perfora-
tions), anticoagulation reversal (33%), covered stent implantation (33%),
emergency surgical evacuation (17%), and pericardiocentesis (17%).
4 | DISCUSSION
To the best of our knowledge, this is the first study describing the
prevalence and outcomes of balloon undilatable CTOs, The main find-
ings were that balloon undilatable CTOs: (1) are common (12% of
all CTOs); (2) often require use of aggressive vessel preparation techni-
ques; and (3) are associated with lower technical and procedural suc-
cess and higher in-hospital complication rates.
Balloon undilatable CTOs are lesions that fail to expand despite
multiple balloon inflations after successful guidewire crossing, and bal-
loon advancement within the target lesion. Stenting such lesions should
be avoided until after adequate dilation has been achieved to prevent
stent underexpansion, which in turn may predispose to in-stent reste-
nosis and stent thrombosis [10,11,16]. As anticipated, balloon undilat-
able lesions were more likely to also be balloon uncrossable (in 44%),
and to have longer length and heavy calcification.
The frequency of balloon undilatable lesions was high in our
cohort, likely in part due to treatment of increasingly complex CTOs
over time, such as lesions with severe calcification. Fernandez et al.
[17] investigated 6,882 consecutive PCIs in a single center study
between 2007 and 2011 and reported 58 ‘balloon failure’ cases
(0.84%). Balloon failure was defined as balloon failure to cross in 36
patients [16 of whom had CTOs], and balloon failure to expand in 22
cases [2 of which were CTOs]). Balloon failure cases were treated with
the combination of laser and/or rotablation atherectomy, with 91%
overall success rate. In the ELLEMENT (Excimer Laser LEsionModifica-
tion to Expand Non-dilatable sTents) multicenter pilot study 28 consec-
utive cases were enrolled with stent underexpansion treated with
excimer laser atherectomy between 2009 and 2011; however, the
study focused on the technical approach and not the prevalence of
these lesions [18].
Balloon undilatable lesions had lower technical and procedural suc-
cess and higher risk for complications. There are several treatment
options for balloon undilatable lesions, which can be applied in an algo-
rithmic fashion (Figure 2) [19]. The first step usually involves high-
pressure inflation with a 1:1 sized non-compliant balloon (the median
maximum inflation pressure was 25 atm [IQR 20–30] in our cohort)
[20]. High-pressure balloon inflation is the simplest and most widely
available technique that can be repeated multiple times; however, it
carries risk for balloon rupture and/or vessel perforation. If balloon rup-
ture occurs, coronary angiography should be immediately performed
after removal of the ruptured balloons to determine whether coronary
perforation has occurred. Occasionally two smaller balloons can be
TABLE 2 Angiographic characteristics of the study CTO lesions, classified according to whether they were balloon undilatable or not
Angiographic characteristics
Balloon undilatable lesions Balloon dilatable lesions
P value(n552, 12%) (n5373, 88%)
CTO target vessel, n (%) 0.239
RCA (%) 25 (48) 191 (55)
LCX (%) 8 (17) 75 (23)
LAD (%) 18 (35) 77 (22)
Other (%) 1 (2) 6 (2)
CTO length (mm)b 40 (20, 50) 30 (15, 40) 0.016
Vessel diameter (mm)b 3 (3, 3) 3 (3, 3) 0.092
Proximal cap ambiguity, n (%) 19 (38) 107 (35) 0.632
Side branch at proximal cap, n (%) 28 (55) 146 (48) 0.342
Blunt stump/no stump, n (%) 30 (60) 162 (51) 0.251
Interventional collaterals, n (%) 41 (43) 174 (56) 0.083
Moderate/severe calcification, n (%) 41 (87) 169 (54) <0.001
Moderate/severe tortuosity, n (%) 25 (53) 125 (40) 0.089
In-stent restenosis, n (%) 12 (25) 59 (19) 0.324
Prior failed CTO PCI, n (%) 13 (26) 67 (21) 0.477
J-CTO scorea 3.261.1 2.56 1.3 <0.001
PROGRESS-CTO scorea 1.561.2 1.56 1.0 0.881
PROGRESS-CTO Complications scorea 3.961.7 3.16 2.0 0.005
Abbreviations: CTO, chronic total occlusion; RCA, right coronary artery; LCX, left circumflex artery; LM segment; LAD, left anterior descending artery;
PCI, percutaneous coronary intervention; J, Japan; PROGRESS, Prospective Global Registry of Chronic Total Occlusion Interventions.
aMean6 SD.
bMedian (IQR).
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inflated side-by-side within the undilatable coronary segment to facili-
tate vessel expansion. Balloon inflation can also be repeated after
inserting one (or more) buddy wire(s) through the lesion [21–23].
Another option is to use an AngioSculpt (Spectranetics, Fremont, CA),
or a cutting balloon [24] to create controlled incisions in the vessel
wall that may assist with vessel expansion. However, these devices
may be challenging to deliver to the lesion due to lack of flexibility
caused by the wires or cutting blades and can be facilitated by using
strong guide catheter support, for example by use of one or more
guide catheter extensions (mother-daughter-granddaughter technique
[25]) or by using side branch anchoring [24,26,27]. The AngioSculpt,
and the cutting balloon were utilized in 10 and 9%, respectively of
our cases.
Additional strategies for expanding balloon undilatable lesions
include laser (used in 13% in our cohort), or atherectomy (RA was used
in 19% and orbital atherectomy in 4% of lesions in our study)
[17,28,29]. Laser is easy to use and can be advanced over any standard
0.014 inch guidewire, whereas both orbital and rotational atherectomy
require use of a specialized, thinner guidewire. Laser can be used even
in previously stented lesions, whereas rotational or orbital atherectomy
are avoided in this setting. In “balloon undilatable” lesions due to in-
stent restenosis, laser can be activated with simultaneous contrast
injection to modify the calcified plaque [30]. The LEONARDO study
(Early outcome of high energy Laser [Excimer] facilitated coronary
angioplasty ON hARD and complex calcified and balloOn-resistant cor-
onary lesions [31]) analyzed 80 patients with 100 lesions of treated
TABLE 3 Technical characteristics of the study CTO lesions, classified according to whether they were balloon undilatable or not
Technical characteristics*
Balloon undilatable
lesions (n552, 12%)
Balloon dilatable
lesions (n5 373, 88%) P value
Bilateral injection, n (%) 36 (75) 248 (73) 0.763
Crossing strategies used
 AWE, n (%) 41 (79) 312 (84) 0.387
 ADR, n (%) 18 (35) 114 (31) 0.554
 Retrograde technique, n (%) 24 (46) 124 (33) 0.067
Final crossing strategy 0.215
 AWE, n (%) 23 (44) 104 (55)
 ADR, n (%) 11 (21) 72 (21)
 Retrograde, n (%) 18 (35) 84 (24)
First crossing strategy 0.084
 AWE, n (%) 36 (71) 293 (83)
 ADR, n (%) 4 (7) 23 (7)
 Retrograde, n (%) 11 (22) 39 (11)
IVUS use overall 31 (65) 155 (42) 0.003
 Proximal cap identification, n (%) 2 (7) 11 (7) 1.000
 Guide wiring, n (%) 8 (26) 31 (20) 0.474
 Stent sizing., n (%) 10 (32) 88 (57) 0.001
 Guide reverse CART reentry, n (%) 1 (3) 3 (2) 0.521
 Stent optimization, n (%) 22 (71) 87 (56) 0.126
Balloon uncrossable lesions, n (%) 23 (44) 26 (7) <0.001
Access site
 Right femoral access site, n (%) 41 (79) 294 (79) 1.000
 Left femoral access site, n (%) 27 (52) 172 (46) 0.432
 Right radial access site, n (%) 22 (42) 128 (34) 0.259
 Left radial access site, n (%) 17 (33) 94 (25) 0.249
Technical success, n (%) 48 (92) 367 (98) 0.024
Procedural characteristics** (n552, 12%) (n5363, 88%)
Procedural success, n (%) 45 (88) 346 (96) 0.034
Procedure time (min)a 195 (115, 262) 141 (97, 205) 0.007
Contrast volume (mL)a 284 (185, 315) 262 (200, 350) 0.642
Fluoroscopy time (min)a 67 (40, 104) 49 (30, 76) 0.007
Patient AK dose (Gray)a 3 (2, 4) 3 (2, 4) 0.083
Abbreviations: ADR, antegrade dissection reentry; AK, air kerma; AWE, antegrade wire escalation; CART, controlled antegrade and retrograde subintimal
tracking; IVUS, intravascular ultrasound.
aMedia n (IQR).
bMean6 SD.
*per lesion; ** per patient.
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with high (60–80 mJ/mm2, 80 Hz) and standard (60 mJ/mm2, 40 Hz)
energy laser. As primary indication for laser therapy, 37% was balloon
failure and 11% were CTOs. The overall technical success rate was
93.7%, without perforations, no reflow phenomenon, target vessel dis-
section, or acute vessel closure. With use of higher laser energy, the
initial technical (42.7–93.7%, P<0.001) and procedural (42.7–91.7%,
P<0.001) success improved significantly. Use of laser with simultane-
ous contrast injection should in general be avoided in de novo lesions
due to high rate of perforation or dissection [32].
Insertion of specialized guidewires for atherectomy should be per-
formed with caution, ideally using the trapping technique that can be
performed with a standard balloon, a dedicated balloon (Trapper
balloon, Boston Scientific, Natick, MA), or guide extension catheter
with integrated trapping balloon (TrapLiner, Vascular Solutions, Minne-
apolis, MN). Tian et al. compared the short- and long-term outcomes of
RA, plain old balloon angioplasty, and cutting balloon angioplasty
before stent implantation in heavily calcified lesions [33]. In contrast to
our study, they found no difference in the incidence of perforation (0.0
vs. 0.0 vs. 0.0%) or no reflow phenomenon (0.0 vs. 0.0 vs. 0.3%,
P>0.99) with atherectomy. Similarly, there was no difference in the
incidence of MACE (14.6 vs. 12.3 vs. 8.3%, P50.2), all-cause death
(9.8 vs. 8.2 vs. 4.5%, P50.18), and target lesion revascularization (5.2
TABLE 4 Outcomes of various techniques used to treat balloon undilatable lesions
Technique Use/lesion
Technical
success
Procedural
success
MACE
overall Perforationa
High-pressure balloon inflation, n (%) 33 (64) 33 (100) 31 (94) 2 (6) 3 (9)
AngioSculpt, n (%) 7 (14) 7 (100) 7 (100) 0 (0) 0 (0)
Cutting balloon, n (%) 8 (15) 8 (100) 8 (100) 0 (0) 3 (20)
Laser atherectomy, n (%) 11 (21) 11 (100) 10 (91) 0 (0) 3 (14)
RA, n (%) 16 (31) 14 (88) 14 (88) 1 (6) 2 (13)
Orbital atherectomy, n (%) 3 (6) 3 (100) 3 (100) 0 (0) 0 (0)
Other, n (%) 4 (8) 4 (100) 4 (100) 1 (25) 0 (0)
Other technique refers to buddy wire and Chocolate balloon (Trireme Medical Inc., Pleasanton, CA).
Abbreviation: MACE, major adverse cardiac events; RA, rotational atherectomy.
aAmong CTO PCI for undilatable lesions 6 perforation were detected (in 4 cases 2 or more techniques were used, whereas in the remaining 2 cases
only one technique was used [cutting balloon; RA]).
TABLE 5 Procedural complications during the study CTO interventions, classified according to whether the target lesion was balloon undilat-
able or not
Procedural complications
Balloon undilatable
lesions (n552, 12%)
Balloon dilatable
lesions (n5 363, 88%) P value
In-hospital MACE, n (%) 4 (7.7) 6 (1.7) 0.008
Death 0 (0.0) 1 (0.8) 0.120
Acute MI 0 (0.0) 1 (0.3) 1.000
Stroke 0 (0.0) 1 (0.3) 1.000
Repeat PCI 1 (1.9) 1 (0.3) 0.235
Repeat CABG 1 (1.9) 0 (0.0) 0.008
Pericardial tamponade 3 (5.8) 1 (0.3) 0.007
Tamponade requiring pericardiocentesis 3 (5.8) 1 (0.3) 0.007
Perforation, n (%) 6 (11.5) 7 (1.9) 0.003
Perforation of CTO target vessel, n (%) 5 (9.6) 3 (0.8) <0.001
Perforated collateral, n (%) 1 (1.9) 1 (0.3) 0.235
Perforation type, n (%) <0.001
Ellis class 1 0 (0.0) 0 (0.0)
Ellis class 2 2 (3.8) 1 (0.3)
Ellis class 3 2 (3.8) 3 (0.8)
Ellis class 3—Cavity spilling 2 (3.8) 0 (0.0)
Vascular access complication, n (%) 1 (1.9) 2 (0.6) 0.332
Donor vessel dissection/thrombosis, n (%) 2 (3.9) 6 (1.6) 0.264
Bleeding, n (%) 0 (0.0) 5 (1.4) 1.000
Abbreviations: MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass
graft surgery.
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vs. 3.5 vs. 3.9%, P50.76) at 12 months follow-up. As a last resort, sub-
intimal crossing could be considered, “crushing” the plaque from the
subintimal space, but such techniques are dependent on high level of
expertise in dissection/reentry techniques.
Novel technologies for treating balloon undilatable lesions are in
development or available outside the US. One such technology, cur-
rently available in Europe, is the high-pressure balloon (OPN NC High-
Pressure PTCA Balloon, SIS Medical AG; Winterthur, Switzerland) that
can be inflated up to 35 atmospheres. Also, the lithoplasty balloon
(Shockwave Medical, Fremont, California) can deliver ultrasound shock-
waves (8 pulses/10 sec) achieving tissue modification. Lithoplasty is
currently approved in the US only for peripheral arterial interventions,
but initial application for PCI has been promising [34].
Our study has limitations. First, the study was observational with-
out patient randomization to various treatment modalities. The selec-
tion of applied strategies was based upon the clinical and angiographic
characteristics as assessed by the operator. Second, long-term follow
up of the study patients was not available. Third, there was no core lab-
oratory assessment of the study angiograms or clinical event adjudica-
tion. Fourth, the procedures were performed at dedicated, high volume
CTO centers, by experienced operators, potentially limiting extrapola-
tion to less experienced operators and centers. Fifth, evaluation of cal-
cification was based on angiography, which is known to underestimate
the presence and severity of calcification as compared with intravascu-
lar imaging.
5 | CONCLUSIONS
In conclusion, balloon undilatable lesions are common in contemporary
CTO PCI, often require use of advanced treatment strategies and are
associated with worse clinical outcomes than balloon dilatable lesions.
Additional comparative studies are needed to identify optimal treat-
ment strategies and upcoming new technologies are likely to have a
catalytic impact on optimizing the outcomes of these complex lesions
and patients.
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